β-D-N4-hydroxycytidine

β-D-N4-hydroxycytidine Uses, Dosage, Side Effects, Food Interaction and all others data.

N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions. N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells. It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations. In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine. The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.

Trade Name β-D-N4-hydroxycytidine
Generic N4-Hydroxycytidine
N4-Hydroxycytidine Other Names 4-N-Hydroxycytidine, beta-D-N-4-Hydroxycytidine, Beta-D-N4-hydroxycytidine, N(4)-Hydroxycytidine, NHC, Uridine, 4-oxime, β-D-N4-hydroxycytidine
Type
Formula C9H13N3O6
Weight Average: 259.218
Monoisotopic: 259.080435151
Groups Experimental
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
β-D-N4-hydroxycytidine
β-D-N4-hydroxycytidine

Uses

β-D-N4-hydroxycytidine is a cytidine analog being investigated to treat COVID-19.

N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.

How β-D-N4-hydroxycytidine works

N4-hydroxycytidine is phosphorylated in tissue to the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe. A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.

Toxicity

Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3µM and a CC50 of >10µM.

Food Interaction

No interactions found.

Elimination Route

N4-hydroxycytidine is orally bioavailable in mice but poorly bioavailable in non-human primates.

Innovators Monograph

You find simplified version here β-D-N4-hydroxycytidine

*** Taking medicines without doctor's advice can cause long-term problems.
Share